Kiniksa Pharmaceuticals International, plc(KNSA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-03-31.

Kiniksa Pharmaceuticals International, plc (KNSA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KNSA at 73.2/100 on a 32-signal composite quality model, placing it at rank #138 of 2,961 stocks — the top 5% of the AI-ranked universe. Based on the latest XBRL financial filings (Q1 2026), Kiniksa Pharmaceuticals International, plc reports quarterly revenue of $214.3M, net income of $22.6M, an operating margin of 13.7%. Top institutional holders of KNSA by reported 13-F value include FMR, Rubric Capital Management, BAKER BROS. ADVISORS, based on the most recent SEC filings. KNSA trades on the Nasdaq exchange and files with the SEC under CIK 1730430. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KNSA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kiniksa Pharmaceuticals International, plc directly from SEC EDGAR.